- Home
- GTBP vs EDSA Comparison
GTBP vs EDSA Comparison
Compare GTBP & EDSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GTBP
- EDSA
- Stock Information
- Founded
- GTBP 1965
- EDSA 2015
- Country
- GTBP United States
- EDSA Canada
- Employees
- GTBP N/A
- EDSA N/A
- Industry
- GTBP Biotechnology: Pharmaceutical Preparations
- EDSA Biotechnology: Pharmaceutical Preparations
- Sector
- GTBP Health Care
- EDSA Health Care
- Exchange
- GTBP Nasdaq
- EDSA Nasdaq
- Market Cap
- GTBP 5.5M
- EDSA 6.2M
- IPO Year
- GTBP N/A
- EDSA N/A
- Fundamental
- Price
- GTBP $2.68
- EDSA $1.83
- Analyst Decision
- GTBP Strong Buy
- EDSA Strong Buy
- Analyst Count
- GTBP 1
- EDSA 1
- Target Price
- GTBP $11.00
- EDSA $21.00
- AVG Volume (30 Days)
- GTBP 86.7K
- EDSA 36.4K
- Earning Date
- GTBP 05-15-2025
- EDSA 05-14-2025
- Dividend Yield
- GTBP N/A
- EDSA N/A
- EPS Growth
- GTBP N/A
- EDSA N/A
- EPS
- GTBP N/A
- EDSA N/A
- Revenue
- GTBP N/A
- EDSA N/A
- Revenue This Year
- GTBP N/A
- EDSA N/A
- Revenue Next Year
- GTBP N/A
- EDSA N/A
- P/E Ratio
- GTBP N/A
- EDSA N/A
- Revenue Growth
- GTBP N/A
- EDSA N/A
- 52 Week Low
- GTBP $1.72
- EDSA $1.55
- 52 Week High
- GTBP $4.10
- EDSA $5.59
- Technical
- Relative Strength Index (RSI)
- GTBP 56.17
- EDSA 29.28
- Support Level
- GTBP $2.56
- EDSA $1.88
- Resistance Level
- GTBP $2.82
- EDSA $2.05
- Average True Range (ATR)
- GTBP 0.30
- EDSA 0.08
- MACD
- GTBP 0.01
- EDSA -0.00
- Stochastic Oscillator
- GTBP 65.12
- EDSA 0.00
About GTBP GT Biopharma Inc.
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.
About EDSA Edesa Biotech Inc.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.